Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress

被引:0
作者
Yurou Chu
Xiangxiang Zhou
Xin Wang
机构
[1] Cheeloo College of Medicine,Department of Hematology, Shandong Provincial Hospital
[2] Shandong University,Department of Hematology
[3] Shandong Provincial Hospital Affiliated to Shandong First Medical University,School of Medicine
[4] Shandong University,undefined
[5] Shandong Provincial Engineering Research Center of Lymphoma,undefined
[6] Branch of National Clinical Research Center for Hematologic Diseases,undefined
[7] National Clinical Research Center for Hematologic Diseases,undefined
[8] the First Affiliated Hospital of Soochow University,undefined
来源
Journal of Hematology & Oncology | / 14卷
关键词
Antibody-drug conjugates; Lymphoma; Immunotherapy; Clinical trials;
D O I
暂无
中图分类号
学科分类号
摘要
Antibody-drug conjugates (ADCs) are a promising class of immunotherapies with the potential to specifically target tumor cells and ameliorate the therapeutic index of cytotoxic drugs. ADCs comprise monoclonal antibodies, cytotoxic payloads with inherent antitumor activity, and specialized linkers connecting the two. In recent years, three ADCs, brentuximab vedotin, polatuzumab vedotin, and loncastuximab tesirine, have been approved and are already establishing their place in lymphoma treatment. As the efficacy and safety of ADCs have moved in synchrony with advances in their design, a plethora of novel ADCs have garnered growing interest as treatments. In this review, we provide an overview of the essential elements of ADC strategies in lymphoma and elucidate the up-to-date progress, current challenges, and novel targets of ADCs in this rapidly evolving field.
引用
收藏
相关论文
共 1728 条
[1]  
Le Gouill S(2017)Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma N Engl J Med 377 1250-1260
[2]  
Thieblemont C(2017)Obinutuzumab for the first-line treatment of follicular lymphoma N Engl J Med 377 1331-1344
[3]  
Oberic L(2019)Obinutuzumab in combination with chemotherapy for the first-line treatment of patients with advanced follicular lymphoma: an evidence review group evaluation of the NICE single technology appraisal Pharmacoeconomics 37 975-984
[4]  
Moreau A(2019)Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL Blood 134 1024-1036
[5]  
Bouabdallah K(2017)Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer 117 1736-1742
[6]  
Dartigeas C(2016)Antibody drug conjugates: lessons from 20 years of clinical experience Ann Oncol 27 2168-2172
[7]  
Damaj G(2019)Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study J Clin Oncol 37 3081-3089
[8]  
Gastinne T(2019)Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group) Ann Oncol 30 612-620
[9]  
Ribrag V(2020)Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin Exp Rev Clin Pharmacol 13 1073-1083
[10]  
Feugier P(2020)Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma Exp Opin Investig Drugs 29 1079-1088